Pfizer supplies pricing data to GAO
Executive Summary
Pfizer is turning over drug pricing data subpoenaed by the General Accounting Office, Pfizer CEO Henry McKinnell, PhD, reported Jan. 15. GAO's Jan. 3 subpoena gave the company until Jan. 14 to supply the documents (1"The Pink Sheet" Jan. 14, p. 26). "What was requested was pricing of individual products to individual customers," McKinnell said. "We were prepared to provide that information. However, we wanted to protect confidentiality. We agreed to those protections last week and the data has been provided"...